Company Active LTD

Company profile

Owen Mumford Limited

Medical Shop Diabetic & Sexual Healthcare Products Online

Medical Shop from Owen Mumford selling Diabetic and Sexual Healthcare Products. We offer GlucoTabs, GlucoJuice, Amielle Comfort and many more

CRN
01257871
Founded
1976
Age
50

Overview

Legal name
OWEN MUMFORD LIMITED
Region
South East England
Registered address
PRIMSDOWN INDUSTRIAL ESTATE
WORCESTER ROAD
CHIPPING NORTON
ENGLAND
OX7 5XP
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

2 levels 1 ultimate controller Controls 1
1
Company Active LTD
Owen Mumford Limited
CRN 01257871
2
Direct controller Active LTD
3
Ultimate controller
06066556
CRN 06066556

Company events

Reference milestones and recent Companies House filing stream events.

8 events
30 Jun
2027

Accounts due

Accounts Due

Next accounts due date

17 Jun
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2025

Accounts filed

Accounts

Last accounts made up date

03 Jun
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

14 Nov
2024

Accounts With Accounts Type Group

Accounts PDF pending

AA | Transaction MzQ0MzA0NDQxN2FkaXF6a2N4 | Paper/PDF filed

Published 16 Nov 2024 03:54

13 Aug
1987

Accounts With Accounts Type Full

Accounts Awaiting analysis

AA | Transaction MzkyNjA5MDdhZGlxemtjeA

Published 26 Nov 2024 10:38

13 Aug
1987

Legacy

Annual-return

363 | Transaction MjE1ODI1ODBhZGlxemtjeA

Published 26 Nov 2024 10:38

10 May
1976

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2020
Funded years
2020, 2025
Age at first award
44 years

Projects

2025 Feasibility Studies Lead participant

Remanufacturing for a Sustainable Future in Combination Injection Devices (ReSCid)

1 Jan 2025 to 30 Jun 2025

Awarded
£29,667
Total cost £29,667

Combination drug devices combine a pharmaceutical drug with an injection device, essential for the efficacy of many drugs, especially novel modalities like biologics and nucleic acids. As these novel drug modalities increase, so does the need for combination devices. To ensure a sustainable future for the pharma industry, targeting this component of their...

2020 Collaborative R&D Lead participant

Design of a Vaccine-specific Autoinjector Device to provide a long-term pandemic solution for the UK

1 Dec 2020 to 30 Nov 2021

Awarded
£355,559
Total cost £444,449

The UK Healthcare system faces an enormous challenge to facilitate the administration of a population-wide immunisation programme against COVID-19\. The widespread nature of the process of vaccination has meant that, until now, there has never been a pharmaco-economic justification that could bear the additional costs of vaccination using a self-administr...

Product types

Collaborative R&D Feasibility Studies